High-Risk Patients With MM Show Favorable Outcomes After HSCT
Melissa BadamoMyeloma | November 14, 2024

A study presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology demonstrated favorable outcomes among high-risk patients with newly diagnosed multiple myeloma who received autologous HSCT consolidation.

Advertisement
Advertisement

Advertisement
Advertisement
Editorial Board

Podcasts

Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Naval Daver, MDThe HemOnc Pulse | October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Mazyar Shadman, MD, MPHThe HemOnc Pulse | September 27, 2024
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 17, 2024
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Afaf Osman, MDThe HemOnc Pulse | August 9, 2024
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 26, 2024
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 16, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | September 12, 2024
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.

Trending on MashupMD